Last reviewed · How we verify
Placebo to glipizide
Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes.
Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo to glipizide |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glipizide is a second-generation sulfonylurea that binds to and closes ATP-sensitive potassium channels on the surface of pancreatic beta cells. This closure depolarizes the cell membrane, triggering calcium influx and subsequent insulin exocytosis. The increased circulating insulin reduces blood glucose levels in patients with type 2 diabetes mellitus.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Dizziness
- Headache
- Gastrointestinal disturbance
Key clinical trials
- A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (PHASE3)
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) (PHASE3)
- Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) (PHASE3)
- Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) (PHASE3)
- An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) (PHASE3)
- Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics (PHASE3)
- Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to glipizide CI brief — competitive landscape report
- Placebo to glipizide updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI